I have been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. My current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. I have recently moved to Washington University in St Louis as the Director, Cardio-Oncology Center of Excellence. I am the Deputy Editor for JACC Cardio-Oncology and I am at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continue to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. I am the current President of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Roche(MODEST), Bristol-Myers Squibb Company (MODEST), Prothena(MODEST), Acorda Therapeutics, Inc(SIGNIFICANT), Eli Lilly and Company(MODEST), Pfizer Inc(MODEST)